BioPharma Resources

Drug Trial Radar · NCT00622284

Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes

A Randomised Double-blind, Active-controlled Parallel Group Efficacy and Safety Study of BI 1356 ( 5.0 mg, Administered Orally Once Daily) Compared to Glimepiride Over Two Years in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy

Last checked: Nov 19, 2026Latest source record: Jan 29, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,560 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,560

Actual

Start

Feb 2008

Primary completion

Dec 2010

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Feb 25, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5.0 mg daily) compared to glimepiride given for 104 weeks as add-on therapy to preferably \> 1500 mg metformin in patients with type 2 diabetes mellitus with insufficient glycaemic control

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • Placebo identical to BI 1356 5mgDrug

    Placebo tablet once daily

  • Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mgDrug

    Placebo tablets once daily

  • BI 1356Drug

    5mg, once daily in the morning for 104 weeks

  • GlimepirideDrug

    1mg or 2mg or 3mg or 4mg in the morning for 104 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HbA1c Change From Baseline at Week 52Time frame: Baseline and week 52
  2. HbA1c Change From Baseline at Week 104Time frame: Baseline and week 104

Locations

221 sites in 16 countries. Site status is shown where the registry gives one.

  • 1218.20.10033 Boehringer Ingelheim Investigational Site

    Tempe, Arizona

  • 1218.20.10003 Boehringer Ingelheim Investigational Site

    Chula Vista, California

  • 1218.20.10020 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 1218.20.10035 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 1218.20.10037 Boehringer Ingelheim Investigational Site

    Los Gatos, California

  • 1218.20.10034 Boehringer Ingelheim Investigational Site

    West Palm Beach, Florida

  • 1218.20.10023 Boehringer Ingelheim Investigational Site

    Indianapolis, Indiana

  • 1218.20.10030 Boehringer Ingelheim Investigational Site

    Topeka, Kansas

  • 1218.20.10028 Boehringer Ingelheim Investigational Site

    St Louis, Missouri

  • 1218.20.10006 Boehringer Ingelheim Investigational Site

    Omaha, Nebraska

  • 1218.20.10022 Boehringer Ingelheim Investigational Site

    Endwell, New York

  • 1218.20.10032 Boehringer Ingelheim Investigational Site

    Cincinnati, Ohio

  • 1218.20.10031 Boehringer Ingelheim Investigational Site

    Columbus, Ohio

  • 1218.20.10013 Boehringer Ingelheim Investigational Site

    Mentor, Ohio

  • 1218.20.10045 Boehringer Ingelheim Investigational Site

    Perrysburg, Ohio

  • 1218.20.10042 Boehringer Ingelheim Investigational Site

    Oklahoma City, Oklahoma

  • 1218.20.10024 Boehringer Ingelheim Investigational Site

    Philadelphia, Pennsylvania

  • 1218.20.10002 Boehringer Ingelheim Investigational Site

    Greer, South Carolina

  • 1218.20.10007 Boehringer Ingelheim Investigational Site

    San Antonio, Texas

  • 1218.20.10036 Boehringer Ingelheim Investigational Site

    Murray, Utah

  • 1218.20.10029 Boehringer Ingelheim Investigational Site

    Salt Lake City, Utah

  • 1218.20.10009 Boehringer Ingelheim Investigational Site

    Federal Way, Washington

  • 1218.20.10026 Boehringer Ingelheim Investigational Site

    Renton, Washington

  • 1218.20.35201 Boehringer Ingelheim Investigational Site

    Sofia, Bulgaria

  • 1218.20.35202 Boehringer Ingelheim Investigational Site

    Sofia, Bulgaria

  • 1218.20.35203 Boehringer Ingelheim Investigational Site

    Sofia, Bulgaria

  • 1218.20.35207 Boehringer Ingelheim Investigational Site

    Sofia, Bulgaria

  • 1218.20.35204 Boehringer Ingelheim Investigational Site

    Stara Zagora, Bulgaria

  • 1218.20.45006 Boehringer Ingelheim Investigational Site

    Aalborg, Denmark

  • 1218.20.45001 Boehringer Ingelheim Investigational Site

    Aarhus C, Denmark

  • 1218.20.45011 Boehringer Ingelheim Investigational Site

    Aarhus C, Denmark

  • 1218.20.45013 Boehringer Ingelheim Investigational Site

    Aarhus C, Denmark

  • 1218.20.45002 Boehringer Ingelheim Investigational Site

    Hvidovre, Denmark

  • 1218.20.45003 Boehringer Ingelheim Investigational Site

    København NV, Denmark

  • 1218.20.45007 Boehringer Ingelheim Investigational Site

    Odense, Denmark

  • 1218.20.3308A Boehringer Ingelheim Investigational Site

    Joué Les Tours, France

  • 1218.20.3308C Boehringer Ingelheim Investigational Site

    Joué Les Tours, France

  • 1218.20.3308D Boehringer Ingelheim Investigational Site

    Joué Les Tours, France

  • 1218.20.3308E Boehringer Ingelheim Investigational Site

    Joué Les Tours, France

  • 1218.20.3308F Boehringer Ingelheim Investigational Site

    Joué Les Tours, France

Showing 40 of 221 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.